Company overview
Personalis provides advanced genomic sequencing and analysis services for precision oncology, including the ACE Technology platform to interrogate difficult genome regions and ImmunoID NeXT for multidimensional tumor profiling. They offer NeXT Personal, an ultra-sensitive liquid biopsy assay for minimal residual disease (MRD) detection using whole genome sequencing on FFPE tissue. Personalis operates an on-site CAP-accredited clinical lab to support biopharma in developing next-generation cancer therapies and diagnostics.
Personalis is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include personalis, precision oncology, genomic sequencing, liquid biopsy, mrd testing, neoantigen analysis.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.personalis.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- personalis, precision oncology, genomic sequencing, liquid biopsy, mrd testing, neoantigen analysis, tumor profiling
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What genomic technologies does Personalis offer for oncology R&D?
- Personalis offers ACE Technology for interrogating difficult genome regions, ImmunoID NeXT for multidimensional tumor sequencing, and NeXT Personal liquid biopsy for high-sensitivity MRD detection tracking 1800 variants.
- Does Personalis have regulatory accreditations for clinical testing?
- Yes, Personalis operates an on-site CAP-accredited clinical genomics lab to support precision oncology diagnostics and therapies.
- What services support biopharma in cancer therapy development?
- Personalis provides neoantigen identification for cancer vaccines, comprehensive tumor profiling, and liquid biopsy assays to advance precision oncology from R&D to commercialization.
Related editorial coverage
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Next-Generation Sequencing MEA: Impact on Precision Oncology Treatment Selection
- AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Explore lab tools and QA/QC resources for R&D teams.
